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Introduction: A total of 192 invasive Streptococcus pneumoniae isolates, from serotypes 11A, 15B/C 
and 23A (not included in the conjugated vaccines), were collected in Colombia between 1994 and 2014 
as part of the activities of the Network surveillance system for the causative agents of pneumonia and 
meningitis (SIREVA II). 
Objective: To determine the molecular characteristics of invasive S. pneumoniae isolates from serotypes 
11A, 15B/C and 23A in Colombia from 1994 to 2014.
Materials and methods: The molecular characterization of the isolates was carried out through Pulse-
Field Gel Electrophoresis (PFGE) and Multilocus Sequence Typing (MLST).
Results: Serotype 11A showed one clonal group represented by ST62. Serotype 15B/C was composed 
of three groups associated with Netherlands15B-37 ST199 (28.75%), ST8495 (18.75%), and SLV (Single-
Locus Variant) of ST193 (21.25%). Isolates from serotype 23A were gathered in three clonal groups, with 
70.21% closely related to ST42, 17.02% to Colombia23F-ST338, and 6.38% to Netherlands15B-37 ST199.
Conclusion: Clones Colombia23F-ST338 and Netherlands15B-ST199 covered more serotypes than 
those previously found by other authors, including serotype 23A. These analyses reveal the importance 
of capsular switching in the spreading of successful clones among non-vaccine serotypes causing 
invasive pneumococcal disease.
Key words: Vaccines, conjugate; pneumonia; meningitis; pneumococcal infections; multilocus sequence 
typing; electrophoresis, gel, pulsed-field. 
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Caracterización molecular de los serotipos no vacunales 11A, 15 B/C y 23A de Streptococcus 
pneumoniae recuperados de aislamientos invasivos en Colombia
Introducción. En Colombia se recolectaron 192 aislamientos invasivos de Streptococcus pneumoniae 
de los serotipos 11A, 15B/C y 23A (no incluidos en las vacunas conjugadas) entre 1994 y 2014, 
como parte de las actividades del Sistema de Redes de Vigilancia de los Agentes Responsables de 
Neumonías y Meningitis Bacterianas (SIREVA II).
Objetivo. Determinar las características moleculares de aislamientos invasivos de los serotipos 11A, 
15B/C y 23A de S. pneumoniae recolectados en Colombia entre 1994 y 2014.
Materiales y métodos. La caracterización molecular de los aislamientos se hizo mediante electroforesis 
en gel de campo pulsado (Pulse-Field Gel Electrophoresis, PFGE) y por tipificación de secuencias 
multilocus (Multilocus Sequence Typing, MLST).
Resultados. El serotipo 11A mostró un grupo clonal representado por el ST62, en tanto que el serotipo 
15B/C se distribuyó en tres grupos asociados con los clones Netherlands15B-37 ST199 (28,75 %), ST8495 
(18,75 %) y SLV (variante en un solo locus) de ST193 (21,25 %). Los aislamientos con serotipo 23A se 
agruparon en tres grupos clonales; 70,21 % de ellos estaban estrechamente relacionados con el ST42, 
17,02 % con el Colombia23F-ST338, y 6,38 % con el Netherlands15B-37 ST199.
Conclusión. Los clones Colombia23F-ST338 y Netherlands15B-ST199 encontrados en este estudio 
abarcaron más serotipos de los reportados previamente por otros autores, incluido el serotipo 23A. 
Estos análisis revelan la importancia de la conmutación (switching) capsular en la expansión de clones 
exitosos entre los serotipos no vacunales como causa de enfermedad invasiva neumocócica.
Palabras clave: vacunas conjugadas; neumonía; meningitis; infecciones neumocócicas; tipificación de 
secuencias multilocus; electroforesis en gel de campo pulsado.
doi: https://doi.org/10.7705/biomedica.v34i2.3223
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Streptococcus pneumoniae is an important cause 
of morbidity and mortality in diseases such as otitis, 
pneumonia, sepsis, and meningitis (1). Many of the 
96 serotypes of S. pneumoniae rarely cause serious 
illnesses, but a small number of them cause the 
great majority of invasive pneumococcal diseases 
(IPD) (2,3). In the context of surveillance, serotypes 
recovered from IPDs have been used to guide 
the development of the pneumococcal conjugate 
vaccines (PCV) for prevention of infections in devel-
oped countries. However, S. pneumoniae  population 
biology is not well understood, and neither is the 
relative disease potential of different serotypes (4).
In Colombia, the seven-valent pneumococcal con-
jugate vaccine (PCV7) was added to the childhood 
immunization program in 2009, covering serotypes 
4, 6B, 9V, 14, 18C, 19F and 23F. Subsequently, 
in 2010, the PCV10, which includes the seven 
serotypes of PCV7 and serotypes 1, 5 and 7F, 
was introduced (5). The benefits of introducing 
PCVs have been demonstrated by the high efficacy 
against vaccine serotypes (VT) in invasive diseases 
and in carriage (6). However, the main concern 
after their implementation has been the increase of 
the non-vaccine serotypes (NVT) in IPD cases, as 
reported in several studies and updated information 
from surveillance programs (7,8).
This concern can be attributed to “serotype replace-
ment”, defined by the expansion of preexisting NVT 
pneumococci as a response to vaccine pressure 
(9), and to “serotype switching”, a change of sero-
type in a single clone by alteration or exchange 
of its cps locus (10). Additionally, these effects 
are not completely independent because capsular 
switch variants can subsequently expand within a 
population (11).
Long-term surveillance has become essential to 
understand induced changes in NVT carriage and 
disease, to evaluate the safety and effectiveness 
of pneumococcal vaccines (12), and to identify the 
prevalent serotypes causing invasive diseases. 
Surveillance programs results suggest that the 
prevalence of pneumococci of various serotypes 
not included in the conjugated vaccines is rapidly 
increasing worldwide (e.g., 11, 12, 15, 22F, 23A, 
23B, 33F, 24, 34, and 35B) (13,14).
This study focused on the non-PCV13 serotypes 
11A, 23A, 15B/C, that have dominated in carriage 
after vaccine introduction among other NVTs (15). 
The surveillance on these serotypes in IPD isolates 
is crucial given that they can act as the main 
source for pneumococcal transmission, influencing 
the significant increase of non-PCV13 strains in 
invasive diseases (15). 
In fact, an important increase of these serotypes 
in IPD cases has been reported in England (11A 
and 23A) (16), the United States (15B/C and 23A) 
(17-19), Spain (23A) (20) Denmark (15B) (21), 
and Israel (15B) (22) after the introduction of the 
PCV13.
The analysis of information obtained from patients 
and isolates has become an important tool to 
understand the dynamics of NVT before and after 
vaccine introduction in a population. In Colombia, 
the surveillance of capsular types and antibiotic 
resistance from IPD started in 1994, through the 
SIREVA II program coordinated by the Pan American 
Health Organization (PAHO) (23). The main objective 
of this study was the molecular characterization by 
PFGE and MLST of invasive 11A, 15B/C and 23A 
non vaccine serotypes recovered between 1994 and 
2014 in Colombia.
Materials and methods
Bacterial isolates and patient data
We recovered 192 invasive isolates of serotypes 
11A (n=65), 15B/C (n=80) and 23A (n=47) from 
children and adults, which are kept at the Grupo 
de Microbiología from the Instituto Nacional de 
Salud strain collection as part of the SIREVA II 
surveillance activities from 1994 to 2014. Currently 
this surveillance covers 27 regions of the country 
(5). An IPD case was defined as the isolation of 
S. pneumoniae from a normally sterile body site 
such as blood, cerebrospinal fluid or other normally 
sterile body fluid (5).
Isolate typing was carried out by the Quellung 
reaction using antisera from the Statens Serum 
Institut (Copenhagen, Denmark), while antimicro-
bial susceptibility to penicillin (P), ceftriaxone (CRO), 
trimethoprim-sulfamethoxazole (SXT), chloram-
phenicol (CLO), tetracycline (TET), erythromycin 
(E) and vancomycin (V) was determined by the 
broth microdilution method following the Clinical 
and Laboratory Standards Institute guidelines. 
The nonmeningeal breakpoints were interpreted 
according to these guidelines too (24,25).
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Pulsed-field gel electrophoresis 
Pulsed-field gel electrophoresis (PFGE) was 
performed on all isolates following Vela, et al., 
protocol (26). Genomic DNA was digested with Sma 
I (Promega). Strain R6 and λ ladder marker (New 
England Biolabs) were used as molecular weight 
standards. Streptococcus pneumoniae clones were 
included in the PFGE analyses to verify their 
clonal relation with the isolates (Netherlands15B-37, 
Tennessee23F-4, Colombia23F-26, S. Africa19A -13, 
Hungrary19A -6, Spain9V -3, Spain23F -1, Spain6B -2). 
Band patterns from each isolate were analyzed 
with the GelCompare software in order to obtain 
the dendrograms.
Multilocus sequence typing
Multi-Locus Sequence Typing (MLST) was carried 
out as described previously (27), and nine isolates 
were selected according to the results obtained 
by PFGE. For each clonal group, one isolate was 
chosen in order to determine the sequence type. 
PCR products were sequenced on each strand and 
genetic profiles were analyzed using the software 
available at the pneumococcal MLST website (http://
spneumoniae.mlst.net).
Results
Bacterial isolates and patient data
From 1994 to 2014 the frequency of invasive isolates 
from serotypes 11A, 15B/C, and 23A changed from 
1.9% to 9.5% (figure 1). The isolates were recovered 
from less than 2-year-old patients (20.83%), 2 to 4 
years old (8.33%), 5 to 14 years old (10.93%), 15 
to 50 years old (28.12%), and more than 50 years 
old (26.04%). No particular behavior or population 
preference was found among the three serotypes in 
the different age groups. The age information was 
not available in 5.7% of the cases. The main clinical 
condition caused by the three NVTs was meningitis, 
followed by bacteremia and pneumonia, as detailed 
in table 1.
Sixty two percent of the three NVT isolates showed 
susceptibility to all the antibiotics tested. Trimethoprim/ 
sulfamethoxazole resistance was mainly observed 
in isolates from serotypes 11A and 15B/C, while 
tetracycline resistance predominated in serotypes 
15B/C and 23A (as described in table 2). Most of 
the isolates that presented erythromycin resist-
ance belonged to the serotype 23A (table 2). All 
erythromycin-resistant isolates within the serotype 
23A were also resistant to tetracycline. Multidrug 
resistance to three or more classes of antibiotics 
was observed in 3.1% of all the isolates: 11A: P + 
CLO + SXT + TE (n=1), 15B/C: P + CE + SXT (n=1) 
and 23A: P + TE + SXT (n=1), CLO + SXT + E + TE 
(n=1), P + E + TE (n=2).
Molecular characterization
PFGE results indicated that the different serotypes 
expressing the same sequence type also shared the 
same clonal group. Band patterns in dendrograms 
were very similar. For example, in the 23A PFGE 
analysis, we found not only serotype 23A isolates 
within the ST199 clonal group,  but also serotypes 
15C and 19A. However, the antibiotic resistance 
profile inside the clonal groups is not the same for 
all the isolates, and in the case of the ST199 it can 
vary from antibiotic susceptibility (15C) to penicillin 
and erythromycin resistance (19A).
PFGE results also revealed that 89.23% of 11A 
isolates were closely related in only one clonal group. 
This group was associated with the ST62, while 
10.8% of the isolates were genetically unrelated. 
Serotype 15B/C presented three clonal groups, 
and 28.75% of these isolates were related to the 
Figure 1. Annual frequency of invasive S. pneumoniae isolates 
from non-vaccine serotypes 11A, 15B/C and 23A, compared with 
the frequency of total invasive isolates recovered in Colombia 
from 1994 to 2014 (http://www.ins.gov.co)
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Table 1. Distribution by diagnosis of invasive S. pneumoniae 
isolates, serotypes 11A, 15B/C and 23A, during study period
Diagnosis     11A    15B/C     23A
n % n % n %
Meningitis 16 24.6 36 44.4 16 34.8
Bacteremia 16 24.6 16 19.7 10 21.7
Pneumonia 11 16.9 11 13.5 10 21.7
Not available 22 33.8 17 22.2 11 21.7
Total 65 80 47
393
Biomédica 2017;37:390-6 Non-vaccine serotypes of Streptococcus pneumoniae 
Netherlands15B-37 ST199, 21.25% to the single-
locus variant of ST193, 18.75% to the ST8495, and 
31.25% were genetically unrelated. Serotype 23A 
presented three clonal groups, and the largest group 
gathered 70.2% of the isolates associated with the 
ST42 (the double locus variant of Tennessee23F-4 
clone), while 17.02% of isolates from this serotype 
were closely related to the Colombia23F-ST338, 
6.38 % to the Netherlands15B-37 ST199, and  6.38% 
were genetically unrelated.
Antibiotic resistance profiles per clonal group 
showed similarities among isolates. Nevertheless, 
susceptible and resistant isolates to one, two or 
more antibiotics were found in the same clonal 
group in the three NVT analyses.
Discussion
The widespread use of conjugate vaccines has 
been very effective in reducing IPD cases. However, 
disease increase caused by NVT (“serotype replace-
ment”) has subsequently offset some of these 
reductions (7,8).
NVT surveillance is an issue of concern given its 
relation with invasive diseases affecting less than 
two-year-old children, i.e., the most vulnerable 
population (28). Nevertheless, in this study 20.8% 
of isolates came from less than 2-year-old children, 
and 26.0% from more than 50-year-old adults. In 
this case, the less invasive serotypes, acting as 
“opportunistic pathogens”, would be expected to 
preferentially cause disease in older patients with 
higher levels of comorbidity. These associations 
can be considered to predict which pneumococcal 
vaccine would be recommended according to the 
population group (29).
PFGE results for serotype 11A revealed a clonal 
behavior related to ST62 erythromycin resistance, 
as reported by other authors (30,31). Despite its 
characteristic erythromycin resistant profile, only 
3% of this group of isolates showed resistance to 
this antibiotic during the susceptibility test (table 2). 
Aguinagalde, et al., reported that serotype 11A, 
ST62 invasive isolates are more resistant to 
phagocytosis than other 11A clones. Therefore, 
the isolates that are more resistant to neutrophil 
clearance will have an advantage and persist in 
the nasopharynx to facilitate its clonal expansion 
(31). This divergence could have implications for 
decision-makers making product choices for adult 
pneumococcal vaccination programs.
The carriage prevalence of this NVT has been 
reported after the PCV introduction in Hungary 
(32), Colombia (33), and from invasive diseases in 
Spain (20) and the United States (30). Even when 
this serotype is associated with asymptomatic 
carriage, its importance resides on the significant 
mortality caused by invasive diseases (30).
Harboe, et al., showed that highly encapsulated 
and frequently carried serotypes such as 11A might 
have high mortality rates in healthy people. These 
rates can be comparable to those of serotypes 19F 
and 6B, which were successful in the pre-vaccine 
era (34).
PFGE analyses of serotype 15B/C established 
that the Netherlands15B-37 ST199 clone comprised 
the major clonal group of the dendrogram. This 
sequence type has been found and reported in 
other serotypes, including 19A, 14 and 15B/C (35). 
In the United States, it is known as a penicillin 
susceptible invasive type for serotype 15B/C and an 
intermediately penicillin resistant type for serotype 
19A (36). This clonal complex is successful at 
population level for its adaptation in carriage, otitis 
media, and invasive disease. Therefore, the 15B/C 
isolates can disseminate as the 19A ones and 
cause pneumococcal diseases (17,37). 
Table 2. Resistance of S. pneumoniae isolates from non-vaccine serotypes 11A, 15B/C and 23A (1994-2014 invasive pneumococcal 
diseases surveillance) 
Antibiotic Number of isolates
  11A   15B/C      23A
n   % n % n %
Trimethoprim/sulfamethoxazole 13 20.0 14 17.3   2   4.3
Tetracycline   8 12.3 17 21.1 24 52.2
Penicillin   2 3   7   8.6   6 13.0
Chloramphenicol   2 3   0 0   1   2.2
Erythromycin   2 3   0 0   8 17.4
Ceftriaxone   0 0   1   1.2   0 0
Non-antibiotic resistance 46 70.7 51 62.9 22 47.8
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The single-locus variant (SLV) of ST193 (Greece21-
30), the second most frequent in this study for 
15B/C isolates, has been previously associated with 
serotypes 21 (38) and 19A (38), and with serogroup 
15 (37). According to the MLST database, they 
have been found in the United States, Germany, 
Italy, and the Kingdom of Saudi Arabia, and they 
are distributed at least in eight different serotypes 
(39). During a study of antimicrobial resistance in 
S. pneumonia in Finland, the ST193 predominated 
among the telithromycin resistant isolates, which 
were serotyped as 19A (40).
One of the serotype 23A clonal groups was 
represented by the double locus variant of 
Tennessee23F-4 clone, known as the ST42. Little 
information is available about this sequence type, 
although it is considered the founder of the clonal 
complex CC42, between the serotypes 23A and 
23F (41). Our results indicated that most of the 
isolates associated with this sequence type showed 
antibiotic susceptibility or tetracycline resistance.
All the 23A erythromycin-resistant isolates were 
resistant to tetracycline, and most of them were 
related to the ST338. In this sense, Ramos, et al., 
observed that 53.4% of the Colombian erythromycin-
resistant isolates presented tetracycline resistance 
(42). The sequence type ST338 in Colombia has 
been associated with serotype 19A and 23F (33), 
and it was originally reported from penicillin-non 
susceptible invasive isolates in Colombia, Brazil 
and Iceland between 1989 and 1996 (42,43). 
However, in this study only three isolates showed 
penicillin resistance.
Given that this successful clone covers more than 
one serotype, it would be important to monitor the 
development of resistant isolates through SIREVA 
II surveillance, as done in other countries with the 
successful clone ST199 (44). This ST199 corre-
sponds to the Netherlands15B-37 clone mentioned 
above, with serotype 15B/C occurring in different 
capsular types. 
Our results suggest that the ST199 now covers the 
23A capsular type with three isolates from 2011, 
2012 and 2014, as expected from any successful 
clone. This is only one example of a successful 
clonal complex that can “camouflage” through 
capsular switching in NVTs to cause IPD as a 
response to vaccine pressure.
Here we recovered information from the sequence 
types ST199 and ST338 that cover more than 
two serotypes through capsular switching. In some 
cases, they can act like the predominant clone, 
probably due to their successful mechanisms for 
causing invasive diseases through pneumococci 
replacement (8). 
Continuous surveillance of IPD based on suscep-
tibility analyses, PFGE, MLST, Whole-Genome 
Sequencing, and other techniques, will allow 
us to follow the dynamics of these clones over 
time. However, we need to study pneumococcal 
virulence factors in prevalent clones in order to 
obtain more information regarding the spread of 
successful clones like the Colombia23F-ST338 and 
the Netherlands15B -ST199 among NVTs.
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